158:
142:
354:
403:
382:
214:
272:
245:
282:
519:
567:
Website also says "A Phase 2b study (TRAVERSE) was also initiated in HCC patients whose disease had progressed on or following treatment with sorafenib or who could not tolerate that treatment. In
September 2013, Transgene announced that the TRAVERSE study did not meet its primary endpoint of overall
135:
150:
363:
255:
630:
568:
survival in this challenging-to-treat patient population. Therefore, Pexa-Vec will not be further developed as a second-line treatment for HCC but only in the first-line indication." -
171:
300:
44:
304:
635:
184:
650:
625:
453:
443:
655:
79:
620:
344:
334:
640:
419:
645:
85:
309:
615:
410:
387:
549:
99:
30:
295:
250:
104:
20:
191:
74:
225:
65:
491:
24:
198:
589:
499:
126:
109:
177:
548:
Article gives status as of Aug 2011 but the phase III trial failed its primary endpoint in 2013 and the
231:
507:
213:
55:
418:
on
Knowledge. If you would like to participate, please visit the project page, where you can join
70:
592:
gene (aka RNR) may also be deleted - implied by Oct2016 ref, but not mentioned by Cripe2015. -
165:
495:
51:
597:
573:
557:
531:
503:
480:
287:
601:
577:
561:
535:
511:
484:
353:
609:
402:
381:
415:
593:
569:
553:
527:
476:
277:
125:
271:
244:
307:. Please visit the project page for details or ask questions at
141:
475:
Pexa-vec ? or would pexastimogene devacirepvec be the INN ? -
207:
15:
299:, which recommends that medicine-related articles follow the
352:
149:
471:
We should probably move/rename this to Pexa-vec soon
414:, a collaborative effort to improve the coverage of
33:for general discussion of the article's subject.
631:Unknown-importance hematology-oncology articles
303:and that biomedical information in any article
490:You are right, this page will need moving to
301:Manual of Style for medicine-related articles
197:
157:
8:
376:
239:
552:gives the March 2014 development plan. -
636:Hematology-oncology task force articles
378:
241:
211:
494:, can create a redirect to there from
183:
7:
651:Low-importance pharmacology articles
626:C-Class hematology-oncology articles
408:This article is within the scope of
293:This article is within the scope of
310:Knowledge talk:WikiProject Medicine
230:It is of interest to the following
23:for discussing improvements to the
428:Knowledge:WikiProject Pharmacology
364:the Hematology-oncology task force
14:
656:WikiProject Pharmacology articles
431:Template:WikiProject Pharmacology
621:Low-importance medicine articles
517:
498:, this would be in-keeping with
401:
380:
305:use high-quality medical sources
280:
270:
243:
212:
45:Click here to start a new topic.
448:This article has been rated as
339:This article has been rated as
641:All WikiProject Medicine pages
319:Knowledge:WikiProject Medicine
1:
646:C-Class pharmacology articles
562:23:04, 14 November 2014 (UTC)
422:and see a list of open tasks.
361:This article is supported by
322:Template:WikiProject Medicine
42:Put new text under old text.
602:18:47, 14 October 2016 (UTC)
578:18:55, 14 October 2016 (UTC)
536:18:45, 14 October 2016 (UTC)
50:New to Knowledge? Welcome!
672:
492:pexastimogene devacirepvec
454:project's importance scale
345:project's importance scale
25:Pexastimogene devacirepvec
616:C-Class medicine articles
447:
396:
360:
338:
265:
238:
80:Be welcoming to newcomers
590:ribonucleotide reductase
512:11:12, 10 May 2013 (UTC)
500:talimogene laherparepvec
485:09:35, 10 May 2013 (UTC)
411:WikiProject Pharmacology
357:
220:This article is rated
75:avoid personal attacks
434:pharmacology articles
356:
123:Find medical sources:
100:Neutral point of view
584:RR gene also deleted
296:WikiProject Medicine
105:No original research
256:Hematology-oncology
358:
226:content assessment
129:
86:dispute resolution
47:
468:
467:
464:
463:
460:
459:
375:
374:
371:
370:
325:medicine articles
206:
205:
128:Source guidelines
127:
66:Assume good faith
43:
663:
525:
521:
520:
436:
435:
432:
429:
426:
405:
398:
397:
392:
384:
377:
327:
326:
323:
320:
317:
290:
285:
284:
283:
274:
267:
266:
261:
258:
247:
240:
223:
217:
216:
208:
202:
201:
187:
161:
153:
145:
131:
95:Article policies
16:
671:
670:
666:
665:
664:
662:
661:
660:
606:
605:
586:
550:company website
546:
518:
516:
473:
433:
430:
427:
424:
423:
390:
324:
321:
318:
315:
314:
288:Medicine portal
286:
281:
279:
259:
253:
224:on Knowledge's
221:
121:
116:
115:
114:
91:
61:
12:
11:
5:
669:
667:
659:
658:
653:
648:
643:
638:
633:
628:
623:
618:
608:
607:
585:
582:
581:
580:
545:
542:
541:
540:
539:
538:
472:
469:
466:
465:
462:
461:
458:
457:
450:Low-importance
446:
440:
439:
437:
420:the discussion
406:
394:
393:
391:Low‑importance
385:
373:
372:
369:
368:
359:
349:
348:
341:Low-importance
337:
331:
330:
328:
292:
291:
275:
263:
262:
260:Low‑importance
248:
236:
235:
229:
218:
204:
203:
118:
117:
113:
112:
107:
102:
93:
92:
90:
89:
82:
77:
68:
62:
60:
59:
48:
39:
38:
35:
34:
28:
13:
10:
9:
6:
4:
3:
2:
668:
657:
654:
652:
649:
647:
644:
642:
639:
637:
634:
632:
629:
627:
624:
622:
619:
617:
614:
613:
611:
604:
603:
599:
595:
591:
583:
579:
575:
571:
566:
565:
564:
563:
559:
555:
551:
543:
537:
533:
529:
524:
515:
514:
513:
509:
505:
501:
497:
493:
489:
488:
487:
486:
482:
478:
470:
455:
451:
445:
442:
441:
438:
421:
417:
413:
412:
407:
404:
400:
399:
395:
389:
386:
383:
379:
366:
365:
355:
351:
350:
346:
342:
336:
333:
332:
329:
312:
311:
306:
302:
298:
297:
289:
278:
276:
273:
269:
268:
264:
257:
252:
249:
246:
242:
237:
233:
227:
219:
215:
210:
209:
200:
196:
193:
190:
186:
182:
179:
176:
173:
172:ScienceDirect
170:
167:
164:
160:
156:
152:
148:
144:
140:
137:
134:
130:
124:
120:
119:
111:
110:Verifiability
108:
106:
103:
101:
98:
97:
96:
87:
83:
81:
78:
76:
72:
69:
67:
64:
63:
57:
53:
52:Learn to edit
49:
46:
41:
40:
37:
36:
32:
26:
22:
18:
17:
587:
547:
522:
474:
449:
425:Pharmacology
416:Pharmacology
409:
388:Pharmacology
362:
340:
308:
294:
232:WikiProjects
194:
188:
180:
174:
168:
162:
154:
146:
138:
132:
122:
94:
19:This is the
544:Out of date
31:not a forum
610:Categories
504:Viraltonic
88:if needed
71:Be polite
21:talk page
496:Pexa-vec
316:Medicine
251:Medicine
178:Springer
143:Cochrane
56:get help
29:This is
27:article.
452:on the
343:on the
222:C-class
228:scale.
166:OpenMD
136:PubMed
594:Rod57
570:Rod57
554:Rod57
528:Rod57
477:Rod57
192:Wiley
84:Seek
598:talk
588:The
574:talk
558:talk
532:talk
523:Done
508:talk
481:talk
185:Trip
159:Gale
151:DOAJ
73:and
444:Low
335:Low
199:TWL
612::
600:)
576:)
560:)
534:)
526:-
510:)
502:.
483:)
254::
54:;
596:(
572:(
556:(
530:(
506:(
479:(
456:.
367:.
347:.
313:.
234::
195:·
189:·
181:·
175:·
169:·
163:·
155:·
147:·
139:·
133:·
58:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
